Next 10 |
home / stock / cgem / cgem articles
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily ...
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday...
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-...
U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday. Shares of Skechers U.S.A., Inc. (NYSE:SKX) rose sharply during Frida...
A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3x...
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-...
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers repo...
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) rose ...
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial res...
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Cullinan Therapeutics Inc. (CGEM) is expected to report $-0.9 for Q1 2024